InflaRx (IFRX) to Release Earnings on Thursday

InflaRx (NASDAQ:IFRX) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect InflaRx to post earnings of ($0.17) per share and revenue of $0.0260 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

InflaRx Price Performance

InflaRx stock opened at $0.96 on Thursday. The firm has a 50 day simple moving average of $0.95 and a 200-day simple moving average of $1.16. The stock has a market cap of $64.58 million, a price-to-earnings ratio of -1.41 and a beta of 1.48. InflaRx has a 1-year low of $0.71 and a 1-year high of $1.94.

Hedge Funds Weigh In On InflaRx

A number of large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in InflaRx in the fourth quarter valued at about $135,000. Suvretta Capital Management LLC increased its stake in InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares in the last quarter. Quadrature Capital Ltd acquired a new position in InflaRx during the fourth quarter worth $104,000. Squarepoint Ops LLC raised its holdings in InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after purchasing an additional 135,826 shares during the last quarter. Finally, HRT Financial LP purchased a new stake in InflaRx during the fourth quarter worth $47,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

Analysts Set New Price Targets

IFRX has been the subject of several analyst reports. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of InflaRx in a research note on Tuesday, December 30th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, InflaRx has a consensus rating of “Moderate Buy” and an average target price of $7.50.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.